# Pizarra — PT-pseudo_20a7e91c494c (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20a7e91c494c
Task: 1

Encounter: Urology - outpatient on 13 Feb 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 4.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 0.63 ng/mL/yr
  - Prior PSA: 3.9 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7866596 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30), Atrial fibrillation
  - Problem list / PMHx: Obesity (BMI >30), Atrial fibrillation
  - Current medication: metoprolol
  - Allergies: NKA
  - Additional notes: PSA 4.5 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 73 mL. csPCa 0.79.

Vitals: weight 88 kg, height 176 cm, BMI 28.4, BP 114/76 mmHg, HR 90 bpm. Smoking: Ex-smoker (31 pack-yr, quit 2008).

Chief complaint: Rising PSA to 4.5 ng/mL prompts clinical reassessment following a prior positive biopsy.

History: A 71-year-old, retired postal worker, lives in a ground-floor apartment with his partner, and is divorced. He manages moderate lower urinary tract symptoms (IPSS 11/35) through watchful waiting, complemented by a daily 45-minute walking regimen and weekly alcohol consumption of approximately 23 units. Medical background includes well-controlled atrial fibrillation, currently treated with metoprolol, alongside remote right knee arthroscopy (2015) and managed hypothyroidism with recent endocrine follow-up. Obesity (BMI >30) is noted. He is an ex-smoker (31 pack-yr, quit 2008), attends biannual podiatry visits, and routinely commutes over an hour by train to this clinic without difficulty. He explicitly denies bone pain, haematuria, or unexplained weight loss.

Physical examination: DRE — prostate symmetrically enlarged, smooth and firm texture, absent nodules or asymmetry. General survey shows blood pressure at 114/76 mmHg with a regular heart rate of 90 bpm. Abdominal palpation yields a soft, non-tender field, free of masses or organomegaly.

Patient info: retired postal worker; Divorced; Lives in ground-floor apartment with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 23 units / week; exercise Walking 45 min/day; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care; Endocrine — thyroid screening.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.54 +/- 0.19   (95% CI 0.17-0.89)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.7 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=4.5, age=71.0, psad=0.07, dre_ord=0.0, vol=73.0, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (0.63 ng/mL/yr) against the prior PSA (3.9 ng/mL) to assess the rate of change, which is a critical dynamic factor. It also could not incorporate the specific findings from the mpMRI report (PI-RADS 4) beyond the score itself, nor could it integrate the full context of the laboratory panel or previous notes regarding LUTS or comorbidities (Obesity, AFib) which might influence risk stratification.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier (0.54 +/- 0.19). This wide interval suggests the input features are highly ambiguous for the model. A failure mode is the contradiction between the high csPCa predicted probability (0.7866596) and the Normal DRE finding, which is a key clinical conflict. Another failure mode is the prior positive biopsy status, which makes the question "does he have cancer" less relevant than assessing the current risk profile based on the new PSA rise and PI-RADS 4.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <What is the full lab panel?> -> <If labs show elevated PSA density or other markers, it refines the risk assessment.>
  <PSA history (trend)> -> <What is the full PSA trajectory beyond the headline value?> -> <If the velocity is significantly higher or lower than 0.63 ng/mL/yr, it changes the urgency.>
  <radiology / mpMRI report> -> <What are the full mpMRI findings?> -> <Detailed description of the lesion characteristics (e.g., volume, extent) refines the PI-RADS 4 interpretation.>
  <previous GP / urology consultation notes> -> <What were the specific findings from prior consultations?> -> <Notes might clarify the clinical significance of the prior positive biopsy result in this context.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **mpMRI Report:**
  "PI-RADS 4 lesion in the right peripheral zone, base/mid. PSAD 0.07 ng/mL/mL. csPCa predicted probability 0.7866596."

  **PSA History:**
  "{"date": "Jul 2022", "val": 1.9}, {"date": "Jun 2023", "val": 3.2}, {"date": "Apr 2024", "val": 2.0}, {"date": "Feb 2025", "val": 4.5}"

  **Laboratory Results:**
  "PSA: 4.5 ng/mL, date: 04 Jan 2025, flag: H; Free PSA: 0.51 ng/mL, date: 04 Jan 2025, flag: ; %Free PSA: 11%, date: 04 Jan 2025, flag: L; Creatinine: 96 umol/L, date: 04 Jan 2025, flag: ; eGFR: >60 mL/min/1.73m2, date: 04 Jan 2025, flag: ; Testosterone: 13.6 nmol/L, date: 04 Jan 2025, flag: ; Alkaline phosphatase: 108 U/L, date: 04 Jan 2025, flag: ; LDH: 231 U/L, date: 04 Jan 2025, flag: "

  **Previous Notes:**
  "{"date": "24 Feb 2023", "author": "Dr. R. Visser (GP)", "text": "Clinical review in July 2022 documented a PSA measurement of 2.6 ng/mL, marginally exceeding local reference thresholds. Subsequent monitoring was planned for the following year. Lower urinary tract symptoms remained stable. Baseline urological assessment was initiated given chronological age and the observed PSA trajectory."};
  {"date": "16 Oct 2024", "author": "Dr. R. Visser (GP)", "text": "By April 2024, PSA levels increased to 3.9 ng/mL with a low %Free PSA of 11%. Moderate urinary symptoms were reported without acute retention episodes. Multiparametric MRI and urology re-evaluation were arranged following a prior positive biopsy history and the observed upward trend."}"

NOT RETRIEVED
  get_family_history: Not called because the retrieval of other documents provided sufficient context regarding the clinical picture and risk stratification.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - PSA velocity of 0.63 ng/mL/yr (from prior to current)
  - PI-RADS 4 lesion in the right peripheral zone, base/mid.
  - csPCa predicted probability of 0.7866596.
  - PSA has risen from 3.9 ng/mL (Apr 2024) to 4.5 ng/mL (Feb 2025).

  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  - Prior biopsy status: Positive (None · Negative · ASAP/HGPIN · Positive).

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the combination of a rising PSA velocity, a PI-RADS 4 lesion, and a high predicted csPCa probability, despite the normal DRE. This leans toward the statistical prior of BIOPSY, suggesting the clinical evidence supports the initial suggestion.

[Sections actually revealed in this consultation: psa_trend, radiology_report, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence converges on sampling due to a combination of factors. The key drivers are the PI-RADS 4 lesion, the rising PSA velocity of 0.63 ng/mL/yr, and the high csPCa predicted probability of 0.7866596. This decision is supported by the statistical prior and the retrieved evidence, despite the normal DRE and prior positive biopsy status.

Variables that carried weight: bx=decisive, age=noted, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: psa_trend, radiology_report, laboratory_results, previous_notes
